Harish Pimplaskar

Mr. Pimplaskar has served as Milestone’s VP of Chemistry, Manufacturing, and Controls since 2018. He brings 25 years of experience in CMC, pharmaceutical development, clinical manufacturing, and technology transfer to his role as head of CMC for global drug development of Milestone’s cardiovascular programs. Prior to assuming the leadership role in 2018, he served Milestone as a CMC consultant. Mr. Pimplaskar was formerly the executive director, CMC and pharmaceutical development for Axsome Therapeutics Inc. (Nasdaq: AXSM), where he led Axsome’s pharmaceutical development and clinical manufacturing projects across all research and development programs. Before joining Axsome, Mr. Pimplaskar led the CMC efforts of Chelsea Therapeutics (Nasdaq: CHTP) and played a role in the company’s NDA filing for Northera, a drug for the treatment of Neurogenic Orthostatic Hypotension, which was later approved by the FDA.

Throughout his career, Mr. Pimplaskar has served in progressively senior positions, including at Upsher-Smith Laboratories, Bristol Myers Squibb Company (NYSE: BMY), and Pfizer Consumer Health (NYSE: PFE). His roles have encompassed pharmaceutical development, including formulation development, analytical development, and clinical manufacturing. He is an active member of the American Association of Pharmaceutical Scientists (AAPS) and a charter member of the AAPS Nasal Drug Delivery Focus Group.